世界のHR+/HER2-乳がん市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global HR+/HER2- Breast Cancer Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2935 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、HR+/HER2-乳がんのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（CDK4/6阻害剤、PARP阻害剤、PI3K阻害剤、その他）、用途別市場規模（病院、がんセンター、医療研究・学術機関、外来手術センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・HR+/HER2-乳がんの市場動向 ・企業の競争状況、市場シェア ・HR+/HER2-乳がんの種類別市場規模（CDK4/6阻害剤、PARP阻害剤、PI3K阻害剤、その他） ・HR+/HER2-乳がんの用途別市場規模（病院、がんセンター、医療研究・学術機関、外来手術センター、その他） ・HR+/HER2-乳がんの北米市場規模2016-2027（アメリカ、カナダ） ・HR+/HER2-乳がんのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・HR+/HER2-乳がんのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・HR+/HER2-乳がんの中南米市場規模2016-2027（メキシコ、ブラジル） ・HR+/HER2-乳がんの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Jiangsu HengRui Medicine、Odonate Therapeutics、Radius Pharmaceuticals、Immunomedics、Roche Group、Syndax Pharmaceuticals、Merck、Eagle Pharmaceuticals、Merrimack Pharmaceuticals、GlaxoSmithKline、Millennium Pharmaceuticals、Bayer） ・結論

Market Analysis and Insights: Global HR+/HER2- Breast Cancer Market
The global HR+/HER2- Breast Cancer market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global HR+/HER2- Breast Cancer market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global HR+/HER2- Breast Cancer market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global HR+/HER2- Breast Cancer market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global HR+/HER2- Breast Cancer market.

Global HR+/HER2- Breast Cancer Scope and Market Size
HR+/HER2- Breast Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global HR+/HER2- Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
CDK4/6 Inhibitors
PARP Inhibitors
PI3K Inhibitor
Others

Segment by Application
Hospitals
Cancer Center
Medical Research and Academic Institutions
Ambulatory Surgical Centers
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Jiangsu HengRui Medicine
Odonate Therapeutics
Radius Pharmaceuticals
Immunomedics
Roche Group
Syndax Pharmaceuticals
Merck
Eagle Pharmaceuticals
Merrimack Pharmaceuticals
GlaxoSmithKline

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HR+/HER2- Breast Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 CDK4/6 Inhibitors
1.2.3 PARP Inhibitors
1.2.4 PI3K Inhibitor
1.2.5 Others
1.3 Market by Application
1.3.1 Global HR+/HER2- Breast Cancer Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Cancer Center
1.3.4 Medical Research and Academic Institutions
1.3.5 Ambulatory Surgical Centers
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global HR+/HER2- Breast Cancer Market Perspective (2016-2027)
2.2 HR+/HER2- Breast Cancer Growth Trends by Regions
2.2.1 HR+/HER2- Breast Cancer Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 HR+/HER2- Breast Cancer Historic Market Share by Regions (2016-2021)
2.2.3 HR+/HER2- Breast Cancer Forecasted Market Size by Regions (2022-2027)
2.3 HR+/HER2- Breast Cancer Industry Dynamic
2.3.1 HR+/HER2- Breast Cancer Market Trends
2.3.2 HR+/HER2- Breast Cancer Market Drivers
2.3.3 HR+/HER2- Breast Cancer Market Challenges
2.3.4 HR+/HER2- Breast Cancer Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top HR+/HER2- Breast Cancer Players by Revenue
3.1.1 Global Top HR+/HER2- Breast Cancer Players by Revenue (2016-2021)
3.1.2 Global HR+/HER2- Breast Cancer Revenue Market Share by Players (2016-2021)
3.2 Global HR+/HER2- Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by HR+/HER2- Breast Cancer Revenue
3.4 Global HR+/HER2- Breast Cancer Market Concentration Ratio
3.4.1 Global HR+/HER2- Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HR+/HER2- Breast Cancer Revenue in 2020
3.5 HR+/HER2- Breast Cancer Key Players Head office and Area Served
3.6 Key Players HR+/HER2- Breast Cancer Product Solution and Service
3.7 Date of Enter into HR+/HER2- Breast Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans

4 HR+/HER2- Breast Cancer Breakdown Data by Type
4.1 Global HR+/HER2- Breast Cancer Historic Market Size by Type (2016-2021)
4.2 Global HR+/HER2- Breast Cancer Forecasted Market Size by Type (2022-2027)

5 HR+/HER2- Breast Cancer Breakdown Data by Application
5.1 Global HR+/HER2- Breast Cancer Historic Market Size by Application (2016-2021)
5.2 Global HR+/HER2- Breast Cancer Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America HR+/HER2- Breast Cancer Market Size (2016-2027)
6.2 North America HR+/HER2- Breast Cancer Market Size by Type
6.2.1 North America HR+/HER2- Breast Cancer Market Size by Type (2016-2021)
6.2.2 North America HR+/HER2- Breast Cancer Market Size by Type (2022-2027)
6.2.3 North America HR+/HER2- Breast Cancer Market Size by Type (2016-2027)
6.3 North America HR+/HER2- Breast Cancer Market Size by Application
6.3.1 North America HR+/HER2- Breast Cancer Market Size by Application (2016-2021)
6.3.2 North America HR+/HER2- Breast Cancer Market Size by Application (2022-2027)
6.3.3 North America HR+/HER2- Breast Cancer Market Size by Application (2016-2027)
6.4 North America HR+/HER2- Breast Cancer Market Size by Country
6.4.1 North America HR+/HER2- Breast Cancer Market Size by Country (2016-2021)
6.4.2 North America HR+/HER2- Breast Cancer Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe HR+/HER2- Breast Cancer Market Size (2016-2027)
7.2 Europe HR+/HER2- Breast Cancer Market Size by Type
7.2.1 Europe HR+/HER2- Breast Cancer Market Size by Type (2016-2021)
7.2.2 Europe HR+/HER2- Breast Cancer Market Size by Type (2022-2027)
7.2.3 Europe HR+/HER2- Breast Cancer Market Size by Type (2016-2027)
7.3 Europe HR+/HER2- Breast Cancer Market Size by Application
7.3.1 Europe HR+/HER2- Breast Cancer Market Size by Application (2016-2021)
7.3.2 Europe HR+/HER2- Breast Cancer Market Size by Application (2022-2027)
7.3.3 Europe HR+/HER2- Breast Cancer Market Size by Application (2016-2027)
7.4 Europe HR+/HER2- Breast Cancer Market Size by Country
7.4.1 Europe HR+/HER2- Breast Cancer Market Size by Country (2016-2021)
7.4.2 Europe HR+/HER2- Breast Cancer Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific HR+/HER2- Breast Cancer Market Size (2016-2027)
8.2 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type
8.2.1 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type (2016-2021)
8.2.2 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type (2022-2027)
8.2.3 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type (2016-2027)
8.3 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application
8.3.1 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application (2016-2021)
8.3.2 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application (2022-2027)
8.3.3 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application (2016-2027)
8.4 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Region
8.4.1 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Region (2016-2021)
8.4.2 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America HR+/HER2- Breast Cancer Market Size (2016-2027)
9.2 Latin America HR+/HER2- Breast Cancer Market Size by Type
9.2.1 Latin America HR+/HER2- Breast Cancer Market Size by Type (2016-2021)
9.2.2 Latin America HR+/HER2- Breast Cancer Market Size by Type (2022-2027)
9.2.3 Latin America HR+/HER2- Breast Cancer Market Size by Type (2016-2027)
9.3 Latin America HR+/HER2- Breast Cancer Market Size by Application
9.3.1 Latin America HR+/HER2- Breast Cancer Market Size by Application (2016-2021)
9.3.2 Latin America HR+/HER2- Breast Cancer Market Size by Application (2022-2027)
9.3.3 Latin America HR+/HER2- Breast Cancer Market Size by Application (2016-2027)
9.4 Latin America HR+/HER2- Breast Cancer Market Size by Country
9.4.1 Latin America HR+/HER2- Breast Cancer Market Size by Country (2016-2021)
9.4.2 Latin America HR+/HER2- Breast Cancer Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa HR+/HER2- Breast Cancer Market Size (2016-2027)
10.2 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type
10.2.1 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type (2016-2021)
10.2.2 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type (2022-2027)
10.2.3 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type (2016-2027)
10.3 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application
10.3.1 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application (2016-2021)
10.3.2 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application (2022-2027)
10.3.3 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application (2016-2027)
10.4 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Country
10.4.1 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Country (2016-2021)
10.4.2 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Jiangsu HengRui Medicine
11.1.1 Jiangsu HengRui Medicine Company Details
11.1.2 Jiangsu HengRui Medicine Business Overview
11.1.3 Jiangsu HengRui Medicine HR+/HER2- Breast Cancer Introduction
11.1.4 Jiangsu HengRui Medicine Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.1.5 Jiangsu HengRui Medicine Recent Development
11.2 Odonate Therapeutics
11.2.1 Odonate Therapeutics Company Details
11.2.2 Odonate Therapeutics Business Overview
11.2.3 Odonate Therapeutics HR+/HER2- Breast Cancer Introduction
11.2.4 Odonate Therapeutics Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.2.5 Odonate Therapeutics Recent Development
11.3 Radius Pharmaceuticals
11.3.1 Radius Pharmaceuticals Company Details
11.3.2 Radius Pharmaceuticals Business Overview
11.3.3 Radius Pharmaceuticals HR+/HER2- Breast Cancer Introduction
11.3.4 Radius Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.3.5 Radius Pharmaceuticals Recent Development
11.4 Immunomedics
11.4.1 Immunomedics Company Details
11.4.2 Immunomedics Business Overview
11.4.3 Immunomedics HR+/HER2- Breast Cancer Introduction
11.4.4 Immunomedics Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.4.5 Immunomedics Recent Development
11.5 Roche Group
11.5.1 Roche Group Company Details
11.5.2 Roche Group Business Overview
11.5.3 Roche Group HR+/HER2- Breast Cancer Introduction
11.5.4 Roche Group Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.5.5 Roche Group Recent Development
11.6 Syndax Pharmaceuticals
11.6.1 Syndax Pharmaceuticals Company Details
11.6.2 Syndax Pharmaceuticals Business Overview
11.6.3 Syndax Pharmaceuticals HR+/HER2- Breast Cancer Introduction
11.6.4 Syndax Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.6.5 Syndax Pharmaceuticals Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck HR+/HER2- Breast Cancer Introduction
11.7.4 Merck Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Eagle Pharmaceuticals
11.8.1 Eagle Pharmaceuticals Company Details
11.8.2 Eagle Pharmaceuticals Business Overview
11.8.3 Eagle Pharmaceuticals HR+/HER2- Breast Cancer Introduction
11.8.4 Eagle Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.8.5 Eagle Pharmaceuticals Recent Development
11.9 Merrimack Pharmaceuticals
11.9.1 Merrimack Pharmaceuticals Company Details
11.9.2 Merrimack Pharmaceuticals Business Overview
11.9.3 Merrimack Pharmaceuticals HR+/HER2- Breast Cancer Introduction
11.9.4 Merrimack Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.9.5 Merrimack Pharmaceuticals Recent Development
11.10 GlaxoSmithKline
11.10.1 GlaxoSmithKline Company Details
11.10.2 GlaxoSmithKline Business Overview
11.10.3 GlaxoSmithKline HR+/HER2- Breast Cancer Introduction
11.10.4 GlaxoSmithKline Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.10.5 GlaxoSmithKline Recent Development
11.11 Millennium Pharmaceuticals
11.11.1 Millennium Pharmaceuticals Company Details
11.11.2 Millennium Pharmaceuticals Business Overview
11.11.3 Millennium Pharmaceuticals HR+/HER2- Breast Cancer Introduction
11.11.4 Millennium Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.11.5 Millennium Pharmaceuticals Recent Development
11.12 Bayer
11.12.1 Bayer Company Details
11.12.2 Bayer Business Overview
11.12.3 Bayer HR+/HER2- Breast Cancer Introduction
11.12.4 Bayer Revenue in HR+/HER2- Breast Cancer Business (2016-2021)
11.12.5 Bayer Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global HR+/HER2- Breast Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of CDK4/6 Inhibitors
Table 3. Key Players of PARP Inhibitors
Table 4. Key Players of PI3K Inhibitor
Table 5. Key Players of Others
Table 6. Global HR+/HER2- Breast Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global HR+/HER2- Breast Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global HR+/HER2- Breast Cancer Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global HR+/HER2- Breast Cancer Market Share by Regions (2016-2021)
Table 10. Global HR+/HER2- Breast Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global HR+/HER2- Breast Cancer Market Share by Regions (2022-2027)
Table 12. HR+/HER2- Breast Cancer Market Trends
Table 13. HR+/HER2- Breast Cancer Market Drivers
Table 14. HR+/HER2- Breast Cancer Market Challenges
Table 15. HR+/HER2- Breast Cancer Market Restraints
Table 16. Global HR+/HER2- Breast Cancer Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global HR+/HER2- Breast Cancer Market Share by Players (2016-2021)
Table 18. Global Top HR+/HER2- Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HR+/HER2- Breast Cancer as of 2020)
Table 19. Ranking of Global Top HR+/HER2- Breast Cancer Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by HR+/HER2- Breast Cancer Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players HR+/HER2- Breast Cancer Product Solution and Service
Table 23. Date of Enter into HR+/HER2- Breast Cancer Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 26. Global HR+/HER2- Breast Cancer Revenue Market Share by Type (2016-2021)
Table 27. Global HR+/HER2- Breast Cancer Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global HR+/HER2- Breast Cancer Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global HR+/HER2- Breast Cancer Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global HR+/HER2- Breast Cancer Revenue Market Share by Application (2016-2021)
Table 31. Global HR+/HER2- Breast Cancer Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global HR+/HER2- Breast Cancer Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 34. North America HR+/HER2- Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America HR+/HER2- Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 36. North America HR+/HER2- Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America HR+/HER2- Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America HR+/HER2- Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe HR+/HER2- Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe HR+/HER2- Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe HR+/HER2- Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe HR+/HER2- Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe HR+/HER2- Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America HR+/HER2- Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America HR+/HER2- Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America HR+/HER2- Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America HR+/HER2- Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America HR+/HER2- Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 63. Jiangsu HengRui Medicine Company Details
Table 64. Jiangsu HengRui Medicine Business Overview
Table 65. Jiangsu HengRui Medicine HR+/HER2- Breast Cancer Product
Table 66. Jiangsu HengRui Medicine Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 67. Jiangsu HengRui Medicine Recent Development
Table 68. Odonate Therapeutics Company Details
Table 69. Odonate Therapeutics Business Overview
Table 70. Odonate Therapeutics HR+/HER2- Breast Cancer Product
Table 71. Odonate Therapeutics Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 72. Odonate Therapeutics Recent Development
Table 73. Radius Pharmaceuticals Company Details
Table 74. Radius Pharmaceuticals Business Overview
Table 75. Radius Pharmaceuticals HR+/HER2- Breast Cancer Product
Table 76. Radius Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 77. Radius Pharmaceuticals Recent Development
Table 78. Immunomedics Company Details
Table 79. Immunomedics Business Overview
Table 80. Immunomedics HR+/HER2- Breast Cancer Product
Table 81. Immunomedics Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 82. Immunomedics Recent Development
Table 83. Roche Group Company Details
Table 84. Roche Group Business Overview
Table 85. Roche Group HR+/HER2- Breast Cancer Product
Table 86. Roche Group Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 87. Roche Group Recent Development
Table 88. Syndax Pharmaceuticals Company Details
Table 89. Syndax Pharmaceuticals Business Overview
Table 90. Syndax Pharmaceuticals HR+/HER2- Breast Cancer Product
Table 91. Syndax Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 92. Syndax Pharmaceuticals Recent Development
Table 93. Merck Company Details
Table 94. Merck Business Overview
Table 95. Merck HR+/HER2- Breast Cancer Product
Table 96. Merck Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 97. Merck Recent Development
Table 98. Eagle Pharmaceuticals Company Details
Table 99. Eagle Pharmaceuticals Business Overview
Table 100. Eagle Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 101. Eagle Pharmaceuticals Recent Development
Table 102. Merrimack Pharmaceuticals Company Details
Table 103. Merrimack Pharmaceuticals Business Overview
Table 104. Merrimack Pharmaceuticals HR+/HER2- Breast Cancer Product
Table 105. Merrimack Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 106. Merrimack Pharmaceuticals Recent Development
Table 107. GlaxoSmithKline Company Details
Table 108. GlaxoSmithKline Business Overview
Table 109. GlaxoSmithKline HR+/HER2- Breast Cancer Product
Table 110. GlaxoSmithKline Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 111. GlaxoSmithKline Recent Development
Table 112. Millennium Pharmaceuticals Company Details
Table 113. Millennium Pharmaceuticals Business Overview
Table 114. Millennium Pharmaceuticals HR+/HER2- Breast Cancer Product
Table 115. Millennium Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 116. Millennium Pharmaceuticals Recent Development
Table 117. Bayer Company Details
Table 118. Bayer Business Overview
Table 119. Bayer HR+/HER2- Breast Cancer Product
Table 120. Bayer Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million)
Table 121. Bayer Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global HR+/HER2- Breast Cancer Market Share by Type: 2020 VS 2027
Figure 2. CDK4/6 Inhibitors Features
Figure 3. PARP Inhibitors Features
Figure 4. PI3K Inhibitor Features
Figure 5. Others Features
Figure 6. Global HR+/HER2- Breast Cancer Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Cancer Center Case Studies
Figure 9. Medical Research and Academic Institutions Case Studies
Figure 10. Ambulatory Surgical Centers Case Studies
Figure 11. Others Case Studies
Figure 12. HR+/HER2- Breast Cancer Report Years Considered
Figure 13. Global HR+/HER2- Breast Cancer Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global HR+/HER2- Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global HR+/HER2- Breast Cancer Market Share by Regions: 2020 VS 2027
Figure 16. Global HR+/HER2- Breast Cancer Market Share by Regions (2022-2027)
Figure 17. Global HR+/HER2- Breast Cancer Market Share by Players in 2020
Figure 18. Global Top HR+/HER2- Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HR+/HER2- Breast Cancer as of 2020
Figure 19. The Top 10 and 5 Players Market Share by HR+/HER2- Breast Cancer Revenue in 2020
Figure 20. Global HR+/HER2- Breast Cancer Revenue Market Share by Type (2016-2021)
Figure 21. Global HR+/HER2- Breast Cancer Revenue Market Share by Type (2022-2027)
Figure 22. North America HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America HR+/HER2- Breast Cancer Market Share by Type (2016-2027)
Figure 24. North America HR+/HER2- Breast Cancer Market Share by Application (2016-2027)
Figure 25. North America HR+/HER2- Breast Cancer Market Share by Country (2016-2027)
Figure 26. United States HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe HR+/HER2- Breast Cancer Market Share by Type (2016-2027)
Figure 30. Europe HR+/HER2- Breast Cancer Market Share by Application (2016-2027)
Figure 31. Europe HR+/HER2- Breast Cancer Market Share by Country (2016-2027)
Figure 32. Germany HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific HR+/HER2- Breast Cancer Market Share by Type (2016-2027)
Figure 40. Asia-Pacific HR+/HER2- Breast Cancer Market Share by Application (2016-2027)
Figure 41. Asia-Pacific HR+/HER2- Breast Cancer Market Share by Region (2016-2027)
Figure 42. China HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America HR+/HER2- Breast Cancer Market Share by Type (2016-2027)
Figure 50. Latin America HR+/HER2- Breast Cancer Market Share by Application (2016-2027)
Figure 51. Latin America HR+/HER2- Breast Cancer Market Share by Country (2016-2027)
Figure 52. Mexico HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa HR+/HER2- Breast Cancer Market Share by Type (2016-2027)
Figure 56. Middle East & Africa HR+/HER2- Breast Cancer Market Share by Application (2016-2027)
Figure 57. Middle East & Africa HR+/HER2- Breast Cancer Market Share by Country (2016-2027)
Figure 58. Turkey HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Jiangsu HengRui Medicine Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 62. Odonate Therapeutics Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 63. Radius Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 64. Immunomedics Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 65. Roche Group Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 66. Syndax Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 67. Merck Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 68. Eagle Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 69. Merrimack Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 70. GlaxoSmithKline Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 71. Millennium Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 72. Bayer Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

---